Top-Rated StocksTop-RatedMost-Upgraded StocksMost-Upgraded Apellis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:APLS) $61.58 +7.71 (+14.31%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$53.30▼$61.6950-Day Range$37.14▼$61.5852-Week Range$19.83▼$94.75Volume5.43 million shsAverage Volume1.69 million shsMarket Capitalization$7.30 billionP/E RatioN/ADividend YieldN/APrice Target$66.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Apellis Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside8.0% Upside$66.50 Price TargetShort InterestBearish13.62% of Shares Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews Sentiment0.94Based on 5 Articles This WeekInsider TradingSelling Shares$2.96 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.59) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector604th out of 951 stocksPharmaceutical Preparations Industry279th out of 431 stocks 2.4 Analyst's Opinion Consensus RatingApellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $66.50, Apellis Pharmaceuticals has a forecasted upside of 8.0% from its current price of $61.58.Amount of Analyst CoverageApellis Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.62% of the outstanding shares of Apellis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently decreased by 0.55%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApellis Pharmaceuticals has received a 67.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for deficiency diseases", "Pegcetacoplan", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Apellis Pharmaceuticals is -1.27. Previous Next 2.7 News and Social Media Coverage News SentimentApellis Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Apellis Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 27 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.MarketBeat Follows11 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,956,468.00 in company stock.Percentage Held by InsidersOnly 7.50% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions90.43% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($4.59) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apellis Pharmaceuticals is -11.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apellis Pharmaceuticals is -11.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 31.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Apellis Pharmaceuticals Stock (NASDAQ:APLS)Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Read More APLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLS Stock News HeadlinesDecember 1, 2023 | benzinga.comApellis Pharmaceuticals Options Trading: A Deep Dive into Market SentimentDecember 1, 2023 | finance.yahoo.comApellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue?December 3, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 30, 2023 | finance.yahoo.comVanguard Health Care Fund's Strategic Moves: Spotlight on Ono Pharmaceutical Co LtdNovember 23, 2023 | finance.yahoo.comAPLS Jan 2025 120.000 putNovember 23, 2023 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.7% After Insider SellingNovember 17, 2023 | benzinga.comApellis Pharmaceuticals's Options Frenzy: What You Need to KnowNovember 10, 2023 | markets.businessinsider.comApellis Pharmaceuticals (APLS) Buy Rating: Evaluating the Commercial Potential of Syfovre amid Retinal Vasculitis ConcernsDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 10, 2023 | msn.comGoldman Sachs Initiates Coverage of Apellis Pharmaceuticals (APLS) with Buy RecommendationNovember 9, 2023 | finance.yahoo.comJazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 ViewNovember 8, 2023 | morningstar.comApellis Pharmaceuticals Inc APLSNovember 8, 2023 | markets.businessinsider.comHold Rating on Apellis Pharmaceuticals Amidst Syfovre’s Success and Izervay’s Potential CompetitionNovember 7, 2023 | markets.businessinsider.comHold Rating on Apellis Pharmaceuticals Amid Clinical Wins and Market UncertaintiesNovember 3, 2023 | markets.businessinsider.comBuy Rating on Apellis Pharmaceuticals: Growth Potential from Syfovre Sales and European Market ExpansionNovember 2, 2023 | msn.comMizuho Initiates Coverage of Apellis Pharmaceuticals (APLS) with Neutral RecommendationNovember 2, 2023 | markets.businessinsider.com21 Analysts Have This to Say About Apellis PharmaceuticalsNovember 1, 2023 | seekingalpha.comApellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 1, 2023 | finance.yahoo.comApellis Pharmaceuticals Reports Third Quarter 2023 Financial ResultsOctober 27, 2023 | seekingalpha.comApellis Pharmaceuticals: Looking For Entry Around Crucial Q3 EarningsOctober 27, 2023 | seekingalpha.comApellis Pharmaceuticals: Eye Watering, Roller-Coaster Ride In 2023 To Date - I'm Hitting PauseOctober 26, 2023 | finance.yahoo.comWall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should KnowOctober 25, 2023 | finance.yahoo.comApellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial ResultsOctober 21, 2023 | finance.yahoo.comAPLS Oct 2023 43.000 callOctober 10, 2023 | finance.yahoo.comHow Much Upside is Left in Apellis Pharmaceuticals, Inc. (APLS)? Wall Street Analysts Think 67.65%October 8, 2023 | msn.comJP Morgan Upgrades Apellis Pharmaceuticals (APLS)October 6, 2023 | msn.comRaymond James Maintains Apellis Pharmaceuticals (APLS) Strong Buy RecommendationSee More Headlines Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APLS CUSIPN/A CIK1492422 Webwww.apellis.com Phone(617) 977-5700FaxN/AEmployees767Year Founded2009Price Target and Rating Average Stock Price Target$66.50 High Stock Price Target$93.00 Low Stock Price Target$29.00 Potential Upside/Downside+8.0%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($5.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-652,170,000.00 Net Margins-222.16% Pretax Margin-222.37% Return on Equity-209.10% Return on Assets-69.82% Debt Debt-to-Equity Ratio0.40 Current Ratio4.29 Quick Ratio3.76 Sales & Book Value Annual Sales$75.42 million Price / Sales96.75 Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book31.42Miscellaneous Outstanding Shares118,500,000Free Float109,613,000Market Cap$7.30 billion OptionableNot Optionable Beta0.96 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Cedric Francois M.D. (Age 51)Ph.D., Co-Founder, President, CEO & Director Comp: $1.2MDr. Pascal Deschatelets Ph.D. (Age 53)Co-Founder & Chief Scientific Officer Comp: $688.05kMr. Alec Machiels J.D. (Age 50)MBA, Co-Founder & Director Comp: $72.5kMr. Timothy E. Sullivan (Age 52)CFO & Treasurer Comp: $716.41kMr. David O. Watson Esq. (Age 50)J.D., General Counsel Comp: $675.35kMr. Adam J. Townsend (Age 46)Chief Commercial Officer Comp: $701.61kMs. Nur Nicholson (Age 54)Chief Technical Operations Officer Comp: $373.4kMr. James G. Chopas CPA (Age 57)VP, Corporate Controller & Chief Accounting Officer Ms. Meredith KayaSenior Vice President, Investor Relations & Strategic FinanceMs. Karen Lewis (Age 51)Chief People Officer More ExecutivesKey CompetitorsIntra-Cellular TherapiesNASDAQ:ITCIElanco Animal HealthNYSE:ELANAscendis Pharma A/SNASDAQ:ASNDBridgeBio PharmaNASDAQ:BBIOCerevel TherapeuticsNASDAQ:CEREView All CompetitorsInsiders & InstitutionsBanque Pictet & Cie SASold 4,893 shares on 11/27/2023Ownership: 0.086%Deutsche Bank AGSold 154,072 shares on 11/24/2023Ownership: 0.274%Polar Capital Holdings PlcBought 588,875 shares on 11/22/2023Ownership: 0.889%Cedric FrancoisSold 5,000 sharesTotal: $244,000.00 ($48.80/share)Walleye Capital LLCBought 8,900 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions APLS Stock Analysis - Frequently Asked Questions Should I buy or sell Apellis Pharmaceuticals stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 3 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares. View APLS analyst ratings or view top-rated stocks. What is Apellis Pharmaceuticals' stock price target for 2024? 14 brokers have issued 12-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $29.00 to $93.00. On average, they anticipate the company's share price to reach $66.50 in the next year. This suggests a possible upside of 8.0% from the stock's current price. View analysts price targets for APLS or view top-rated stocks among Wall Street analysts. How have APLS shares performed in 2023? Apellis Pharmaceuticals' stock was trading at $51.71 at the start of the year. Since then, APLS stock has increased by 19.1% and is now trading at $61.58. View the best growth stocks for 2023 here. When is Apellis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our APLS earnings forecast. How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) posted its quarterly earnings data on Wednesday, November, 1st. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.88) by $0.29. The company earned $110.40 million during the quarter, compared to analysts' expectations of $99.05 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 209.10% and a negative net margin of 222.16%. The firm's quarterly revenue was up 400.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.75) earnings per share. What ETFs hold Apellis Pharmaceuticals' stock? ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Jacob Forward ETF (JFWD), Vanguard Russell 2000 Growth ETF (VTWG), Principal Healthcare Innovators ETF (BTEC) and Vanguard Small-Cap Growth ETF (VBK).Harbor Health Care ETF (MEDI). What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO? 18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend. What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI). When did Apellis Pharmaceuticals IPO? (APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO. Who are Apellis Pharmaceuticals' major shareholders? Apellis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Jennison Associates LLC (3.01%), FMR LLC (1.91%), Morgan Stanley (1.36%), Polar Capital Holdings Plc (0.89%), Assenagon Asset Management S.A. (0.87%) and Fiera Capital Corp (0.78%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown. View institutional ownership trends. How do I buy shares of Apellis Pharmaceuticals? Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Apellis Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.Read More This page (NASDAQ:APLS) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.